Drug intelligence / Profile preview

REG3

Development stage: Preclinical
Lead developer: Allergan
Modality: RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

REG3 is an aptamer drug candidate developed by Regado Biosciences. It is being advanced for the treatment of diabetic vasculopathy, leveraging the company's broader aptamer platform, which is recognized for its potential to offer controllable and personalized antithrombotic solutions.

Targets

GPVI (Platelet glycoprotein VI)

Beyond the preview

Go deeper on REG3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REG3.

Explore the full profile